Deka Bank Deutsche Girozentrale Vanda Pharmaceuticals Inc. Transaction History

Deka Bank Deutsche Girozentrale

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 28, 2022	BUY	$10.84 - $16.55 $8,672 - $13,240	800 Added 9.88%	8,900 $101,000
Q4 2021 Feb 02, 2022	BUY	$15.69 - $21.14 $3,138 - $4,228	200 Added 2.53%	8,100 $132,000
Q3 2020 Oct 29, 2020	BUY	$9.32 - $12.02 $73,628 - $94,958	7,900 New	7,900 $73,000
Q4 2019 Feb 04, 2020	SELL	$12.38 - $17.47 $106,468 - $150,242	-8,600 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$12.27 - $15.79 $105,522 - $135,794	-8,600 Reduced 50.0%	8,600 $117,000
Q2 2019 Aug 01, 2019	BUY	$13.37 - $18.85 $88,242 - $124,410	6,600 Added 62.26%	17,200 $248,000
Q1 2019 May 10, 2019	BUY	$17.59 - $31.05 $35,180 - $62,100	2,000 Added 23.26%	10,600 $209,000
Q4 2018 Feb 12, 2019	SELL	$18.97 - $31.47 $37,940 - $62,940	-2,000 Reduced 18.87%	8,600 $220,000
Q3 2018 Nov 09, 2018	SELL	$18.25 - $23.0 $5,475 - $6,900	-300 Reduced 2.75%	10,600 $0
Q1 2018 May 03, 2018	SELL	$14.05 - $20.2 $2,810 - $4,040	-200 Reduced 1.8%	10,900 $181,000
Q3 2017 Nov 06, 2017	BUY	$15.4 - $18.85 $170,940 - $209,235	11,100	11,100 $181,000

158

44.8M

165K

33.6K

Ticker VNDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,561,500
Market Cap $244M
Description
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...

Get notified when there are updates to the investment portfolio of Deka Bank Deutsche Girozentrale, based on Form 13F filings with the SEC.

Stay updated on Deka Bank Deutsche Girozentrale with notifications on news.